Korea, Japan, Europe, and the United States: Why are guidelines for gastric cancer different? [0.03%]
韩国、日本、欧洲和美国的胃癌诊疗为何不同？
Emily E Stroobant,Seong-Ho Kong,Maria Bencivenga et al.
Emily E Stroobant et al.
As a global health concern, gastric cancer management has been systematized by individual countries and regions into regimented guidelines. To explore international differences, we examined the guidelines of Korea, Japan, Europe, and the Un...
Development and application of deep learning-based diagnostics for pathologic diagnosis of gastric endoscopic submucosal dissection specimens [0.03%]
基于深度学习的内镜黏膜下剥离标本病理诊断模型的构建及应用研究
Soomin Ahn,Yiyu Hong,Sujin Park et al.
Soomin Ahn et al.
Background: Accurate diagnosis of ESD specimens is crucial for managing early gastric cancer. Identifying tumor areas in serially sectioned ESD specimens requires experience and is time-consuming. This study aimed to deve...
Transformer-based skeletal muscle deep-learning model for survival prediction in gastric cancer patients after curative resection [0.03%]
基于Transformer的深度学习模型预测胃癌治愈切除术后患者的生存率
Qiuying Chen,Lian Jian,Hua Xiao et al.
Qiuying Chen et al.
Background: We developed and evaluated a skeletal muscle deep-learning (SMDL) model using skeletal muscle computed tomography (CT) imaging to predict the survival of patients with gastric cancer (GC). ...
Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer [0.03%]
FGFR2B低阳性率与胃癌异质性表达相关
Heonwoo Lee,Min-Hee Ryu,In-Seob Lee et al.
Heonwoo Lee et al.
Background: Bemarituzumab, a monoclonal antibody targeting fibroblast growth factor receptor 2b (FGFR2b), is under evaluation in phase 3 trials of gastric cancer (GC) trials. However, data on the characteristics, prognost...
Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination [0.03%]
胃和食管胃交界处癌腹膜转移的预测生物标志物表达异质性
Valentina Angerilli,Matilde Callegarin,Ilaria Govoni et al.
Valentina Angerilli et al.
Background: Temporal and spatial molecular heterogeneity contributes to resistance to targeted and immune therapies in gastric and esophagogastric junction carcinoma (G/EGJ). This study evaluates differences in biomarker ...
The alkylglycerone phosphate synthase sustains the resistance of gastric cancer cells to ferroptosis induced by Apatinib [0.03%]
烷基甘油一磷酸合成酶维持阿帕替尼诱导的胃癌细胞铁死亡抵抗性
Minghao Wang,Qiyuan An,Zhiwei Li et al.
Minghao Wang et al.
Background: Apatinib is a targeted therapy used in the treatment of advanced gastric cancer. However, many gastric cancer patients develop resistance to Apatinib, and the mechanisms underlying this resistance remain uncle...
Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial [0.03%]
卡瑞利珠单抗联合曲妥珠单抗和化疗用于HER2阳性胃或胃食管结合部腺癌的新辅助治疗：一项单臂Ⅱ期临床试验
Yijie Ma,Zhi Li,Chen Wei et al.
Yijie Ma et al.
Background: The impact of neoadjuvant combined chemotherapy, immunotherapy, and targeted therapy on pathologic responses and survival outcomes in HER2-positive locally advanced gastric cancer remains unclear. ...
Zolbetuximab-related gastritis: a case report of the patient with prolonged gastrointestinal symptoms [0.03%]
佐鲁贝妥珠单抗相关胃炎：1例持续性胃肠症状病例报告
Yuya Sugiyama,Hiroki Tanabe,Shion Tachibana et al.
Yuya Sugiyama et al.
A 73-year-old male patient presented with anemia and was diagnosed with unresectable advanced gastric cancer with distant lymph node metastases. The biopsy specimen showed a poorly differentiated adenocarcinoma. Immunohistochemistry was neg...
Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: short-term outcomes of a multicenter, phase II study (OGSG1902) [0.03%]
新辅助多西他赛、奥沙利铂和替吉奥对大型3型或4型胃癌患者的治疗：一项多中心II期研究（OGSG1902）的短期结果
Ryo Tanaka,Shunji Endo,Toshifumi Yamaguchi et al.
Ryo Tanaka et al.
Background: Large type 3 (≥ 8 cm) and type 4 gastric cancers (GCs) have poor prognoses and necessitate multidisciplinary treatment. A multi-institutional phase II study (OGSG1902) was conducted to assess the efficacy and...